My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

48.10 +0.01 (+0.02%)

Official Closing Price Updated: 7:00 PM EST, Dec 22, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More ↗

November 24, 2025

Stocks were up sharply to start the holiday week.

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

November 24, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗

November 24, 2025

The company said that it is discontinuing the trials.

Via Stocktwits

Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗

November 23, 2025

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Via The Motley Fool

Topics Government

Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic ↗

November 21, 2025

Via Stocktwits

2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗

November 22, 2025

Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

Via The Motley Fool

3 Top Dividend Stocks to Buy in November ↗

November 22, 2025

November is a great month to be thankful for opportunities to invest in these fantastic companies.

Via The Motley Fool

Topics Bonds Economy

Big News for Novo Nordisk Stock Investors ↗

November 21, 2025

Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.

Via The Motley Fool

What's Going On With Novo Nordisk Stock? ↗

November 21, 2025

The management team conducted a cost-cutting effort that is likely to result in a more efficient business.

Via The Motley Fool

Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗

November 20, 2025

Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.

Via Benzinga

KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds

November 20, 2025

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a...

Via MarketMinute

Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗

November 20, 2025

Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Via The Motley Fool

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗

November 19, 2025

Via MarketBeat

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War ↗

November 19, 2025

Via MarketBeat

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Should Investors Buy Novo Nordisk Stock Near Its Near 52-Week Low? ↗

November 19, 2025

Novo Nordisk is investing aggressively to improve its pipeline of drugs in development.

Via The Motley Fool

Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future

November 19, 2025

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its...

Via MarketMinute

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗

November 18, 2025

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Via The Motley Fool

Can AI Drive Peloton's Comeback? ↗

November 18, 2025

The market is hopping with interesting news.

Via The Motley Fool

Topics Artificial Intelligence

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗

November 18, 2025

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.

Via Benzinga

Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗

November 18, 2025

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this...

Via Benzinga

Topics Bankruptcy

Price Over Earnings Overview: Novo Nordisk ↗

November 17, 2025

Via Benzinga

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Novo Nordisk Leans Into Affordability Amid Rising Competition ↗

November 17, 2025

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.

Via Benzinga

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control ↗

November 17, 2025

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Via Benzinga

Omeros (OMER) Q3 2025 Earnings Call Transcript ↗

November 17, 2025

Omeros (OMER) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Derivatives Earnings

How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗

November 17, 2025

Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Via Investor's Business Daily

Topics Government

Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗

November 17, 2025

The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.

Via Stocktwits

Topics Artificial Intelligence

This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗

November 17, 2025

Healthcare stocks have far outperformed the broader market over the past month.

Via The Motley Fool

Topics ETFs Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.